Exciting mechanism
Relaxin, activates GR, RXFP1 and PPARγ with neuro-protective effects.
Treating Neurodegeneration with Relaxin
Developing Relaxin as a novel treatment for neurodegeneration.
Hope for the 3 billion sufferers
RELAXIN, A FIRST-IN-CLASS TREATMENT FOR NEURODEGNERATION
Relaxin, a first-in-class drug candidate with disease modifying potential for the treatment of neurodegenerative conditions. These include relapsing remitting and progressive forms of multiple sclerosis, concussion, traumatic brain injury, motor neuron disease, dementia and other neurodegenerative conditions.
Billions of sufferers
There are now more than 3 billion people worldwide who suffer from neurological conditionsThe World Health Organisation.
A huge cost to society
The estimated total economic burden of treating neurodegeneration just in the US is estimated at $800 billion. American Brain Foundation.
Diseases are on the rise
The global prevalence of neurodegenerative diseases is on the rise as our populations age The World Health Organisation.
Neurodegeneration
A neurological condition that affects the brain, spinal cord and/or nerves.
Neurological conditions can be caused by a variety of factors, including genes, the environment, bacterial or viral infections and traumatic injuries or accidents.
A natural hormone
A human hormone, potential as a treatment for neurodegenerative conditions underpinned by scientific rationale.
First-in-Class
A new and unique mechanism of action to treat neurodegeneration
Low Risk
Relaxin's targets are known and the molecule is naturally occurring in the body.
Excellent safety
Relaxin has an excellent safety profile in current clinical studies.
Ample evidence
The preclinical results are supported by the known improvement in stroke patients following treatmnet with relaxin over placebo.
Relaxin; - a new treatment for neurodegeneration
in development targeting CNS indications. It has the potential to modulate the clinical symptoms, be neuroprotective and promote remyelination.
Our passion, commitment and focus
The potential of Relaxin to remyelinate nerves and restore function creates a paradigm shift in our approach neurodegenerative disorders.
Dr Roy Garvin, CEO, BVBiomedical Ltd
Our aim is to meet the challenge of neurodegenerative diseases with transforming technologies able to unlock the potential of relaxin.
Dr Aikaterini Lalatsa, Reader - Deputy Director CRUK Formulation Unit, School of Pharmacy and Biomedical Science, University of Strathclyde
Re:Cognition Health is excited about the opportunity to work with BVbiomedical Ltd. and their new therapeutic compound “relaxin”, intended for the treatment of neurodegenerative diseases. This new “first in class” medication crosses and stabilises the blood brain barrier and can be delivered as a nasal spray. In the elusive search for an intervention to potentially prevent and treat CTE, this could be a solution and change the future for millions of contact sports players.
Dr J Emer MacSweeney, Co-Founder & CEO Re:Cognition Health
A target product profile which is second to none
Relaxin; is a safe and effective treatment. It is being developed as a therapy for neurodegeneration caused by MS, concussion, traumatic brain injury, motor neuron disease, dementia, acute disseminated encephalomyelitis and auto-immune diseases.
Learn more
BVBiomedical Ltd. is a research driven company developing novel therapeutic compounds for use in treating neuro-degenerative diseases.
Contacts
-
- Address
- Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
-
- Phone
-
- +44 751 879 5083
-
- info@bvbiomed.com